KaNDy Therapeutics Company
KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone-related conditions.
Total Funding:
$32 589 510
Headquarters:
Stevenage, Herefordshire, United Kingdom
Funding Status:
M&A
Employee Number:
1-10
Estimated Revenue:
$1M to $10M
Investment Stage:
N/A
Last Funding Type:
Series C
Number Of Exists:
Series C
Technology:
Cancer
Investor Type:
Company
Last Funding Date:
2018-08-29
Investors Number:
5
Founded Date:
2017
Industry:
Longevity